China (Reuters) – 12/02/2022. 11:10
Pfizer Paxilvid is the first oral drug to treat COVID-19
- Paxlovid approved for the treatment of adults with mild to moderate COVID-19
- Pfizer is in active discussions with more than 100 countries about Baxlovid
Awarded by the Medical Products Regulatory Authority in China Conditional approval for a property Pfizer . Baxeloid (PFE.N)COVID-19This makes it the first oral medication developed specifically to treat the disease in the country.
The National Administration of Medicinal Products said that Baxlovid has been approved to treat adults with mild to moderate COVID-19 who have a high risk of progressing to a serious condition, and added that further study on the drug and submission to the authority is needed.
“This is an important milestone in our fight against COVID-19,” a Pfizer representative said in a statement, without providing information about the procurement.
The approval is a boost for Pfizer, which expects sales of $22 billion in 2022 from the treatment.
Pfizer Representative: “This is an important milestone in our fight against COVID-19.”
Pfizer executives confirmed that the company is in active discussions with more than 100 countries about Paxlovid and has the ability to offer 120 million courses if needed.
While a number of vaccines are available worldwide to help prevent infection and serious disease, including the one made by Pfizer, there are limited treatment options for people with COVID-19.
And Pfizer had said in December that the results of the final trial showed that its treatment reduced the rate of hospitalization, or death by 89% for Covid-19 patients at risk of developing serious illness during treatment within three days of symptoms onset, and by 88 % when given within five days.
Pfizer: Final results of the trial showed that baxlovid reduced the rate of hospitalization or death by 89%.
and you pay United State About $530 per course of Paxlovid and $700 per course of competing COVID-19 pills molnupiravir developed by Merck & Co (MRK.N).
China kept the daily number of new COVID-19 patients with confirmed symptoms to less than 250, and sometimes less than 10, last year.
The number is far too small for its population of 1.4 billion and by global standards, thanks to China’s approach of quickly containing any domestic flare-ups as soon as possible and a weeks-long quarantine requirement for most overseas travelers.
China has not yet approved any COVID-19 vaccines developed by foreign pharmaceutical companies, but it had vaccinated 87.1% of its entire population by February 7 using several domestically developed shots.
It was not clear if China was actually in talks with Pfizer to buy the grain.
